Effects of long-term PPI treatment on producing bowel symptoms and SIBO

被引:98
作者
Compare, Debora [1 ]
Pica, Loredana [1 ]
Rocco, Alba [1 ]
De Giorgi, Francesco [1 ]
Cuomo, Rosario [1 ]
Sarnelli, Giovanni [1 ]
Romano, Marco [2 ]
Nardone, Gerardo [1 ]
机构
[1] Univ Naples Federico II, Dept Clin & Expt Med, Gastroenterol Unit, I-80131 Naples, Italy
[2] Univ Naples 2, Dept Clin & Expt Med, Gastroenterol Unit, Naples, Italy
关键词
GERD; IBS; NERD; PPIs; SIBO; PROTON PUMP INHIBITORS; GASTROESOPHAGEAL-REFLUX DISEASE; INTESTINAL BACTERIAL OVERGROWTH; DOUBLE-BLIND; 40; MG; RISK; PANTOPRAZOLE; OMEPRAZOLE; ESOMEPRAZOLE; ESOPHAGITIS;
D O I
10.1111/j.1365-2362.2010.02419.x
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
P>Background Gastroesophageal reflux disease (GERD), including erosive reflux disease and non-erosive reflux disease (NERD), is a chronic disease with a significant negative effect on quality of life. State-of-the-art treatment involves proton pump inhibitors (PPIs). However, relapse of symptoms occurs in the majority of the patients who require recurrent or continuous therapy. Although PPIs are well tolerated, little information is available about gastrointestinal side effects. Aim To evaluate the effects of long-term PPI treatment on development of bowel symptoms and/or small intestinal bacterial overgrowth (SIBO). Methods Patients with NERD not complaining of bowel symptoms were selected by upper endoscopy, 24-h pH-metry and a structured questionnaire concerning severity and frequency of bloating, flatulence, abdominal pain, diarrhoea and constipation. Patients were treated with esomeprazole 20 mg bid for 6 months. Prior to and after 8 weeks and 6 months of therapy, patients received the structured questionnaire and underwent evaluation of SIBO by glucose hydrogen breath test (GHBT). Results Forty-two patients with NERD were selected out of 554 eligible patients. After 8 weeks of PPI treatment, patients complained of bloating, flatulence, abdominal pain and diarrhoea in 43%, 17%, 7% and 2%, respectively. After 6 months, the incidence of bowel symptoms further increased and GHBT was found positive in 11/42 (26%) patients. By a post hoc analysis, a significant (P < 0 center dot 05) percentage of patients (8/42) met Rome III criteria for irritable bowel syndrome. Conclusions Prolonged PPI treatment may produce bowel symptoms and SIBO; therefore, the strategy of step-down or on-demand PPI therapy should be encouraged in GERD.
引用
收藏
页码:380 / 386
页数:7
相关论文
共 45 条
[1]
The endoscopic assessment of esophagitis: A progress report on observer agreement [J].
Armstrong, D ;
Bennett, JR ;
Blum, AL ;
Dent, J ;
deDombal, FT ;
Galmiche, JP ;
Lundell, L ;
Margulies, M ;
Richter, JE ;
Spechler, SJ ;
Tytgat, GNJ ;
Wallin, L .
GASTROENTEROLOGY, 1996, 111 (01) :85-92
[2]
Management strategies for gastroesophageal reflux disease [J].
Bak, YT .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2004, 19 :S49-S53
[3]
BANCEWICZ J, 1990, DISEASES OF THE ESOPHAGUS, VOL 2, P177
[4]
Mortality study of 18 000 patients treated with omeprazole [J].
Bateman, DN ;
Colin-Jones, D ;
Hartz, S ;
Langman, M ;
Logan, RF ;
Mant, J ;
Murphy, M ;
Paterson, KR ;
Rowsell, R ;
Thomas, S ;
Vessey, M .
GUT, 2003, 52 (07) :942-946
[5]
Proton Pump Inhibitors, Irritable Bowel Syndrome, and Small Intestinal Bacterial Overgrowth: Coincidence or Newton's Third Law Revisited? [J].
Chey, William D. ;
Spiegel, Brennan .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2010, 8 (06) :480-482
[6]
Oesophageal acid exposure and altered neurocardiac function in patients with GERD and idiopathic cardiac dysrhythmias [J].
Cuomo, R. ;
De Giorgi, F. ;
Adinolfi, L. ;
Sarnelli, G. ;
Loffredo, F. ;
Efficie, E. ;
Verde, C. ;
Savarese, M. F. ;
Usai, P. ;
Budillon, G. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2006, 24 (02) :361-370
[7]
Effectiveness of Proton Pump Inhibitors in Nonerosive Reflux Disease [J].
Dean, Bonnie B. ;
Gano, Anacleto D., Jr. ;
Knight, Kevin ;
Ofman, Joshua J. ;
Fass, Ronnie .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2004, 2 (08) :656-664
[8]
DUODENAL BACTERIAL OVERGROWTH DURING TREATMENT IN OUTPATIENTS WITH OMEPRAZOLE [J].
FRIED, M ;
SIEGRIST, H ;
FREI, R ;
FROEHLICH, F ;
DUROUX, P ;
THORENS, J ;
BLUM, A ;
BILLE, J ;
GONVERS, JJ ;
GYR, K .
GUT, 1994, 35 (01) :23-26
[9]
Methodology and Indications of H2-Breath Testing in Gastrointestinal Diseases: the Rome Consensus Conference [J].
Gasbarrini, A. ;
Corazza, G. R. ;
Gasbarrini, G. ;
Montalto, M. ;
Di Stefano, M. ;
Basilisco, G. ;
Parodi, A. ;
Satta, P. U. ;
Vernia, P. ;
Anania, C. ;
Astegiano, M. ;
Barbara, G. ;
Benini, L. ;
Bonazzi, P. ;
Capurso, G. ;
Certo, M. ;
Colecchia, A. ;
Cuoco, L. ;
Di Sario, A. ;
Festi, D. ;
Lauritano, C. ;
Miceli, E. ;
Nardone, G. ;
Perri, F. ;
Portincasa, P. ;
Risicato, R. ;
Sorge, M. ;
Tursi, A. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2009, 29 :1-49
[10]
40 mg pantoprazole and 40 mg esomeprazole are equivalent in the healing of esophageal lesions and relief from gastroesophageal reflux disease-related symptoms [J].
Gillessen, A ;
Beil, W ;
Modlin, IM ;
Gatz, G ;
Hole, U .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 2004, 38 (04) :332-340